Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06534671 · ClinicalTrials.gov registry record · Phase 4
Diltiazem in Jervell and Lange-Nielsen Syndrome
A Phase 4 study of Jervell and Lange Nielsen Syndrome, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT06534671: Completed Phase 4 study of Jervell and Lange Nielsen Syndrome, sponsored by Vanderbilt University Medical Center.
NCT06534671 is a Phase 4 study of Jervell and Lange Nielsen Syndrome that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06534671, a Phase 4 study of Jervell and Lange Nielsen Syndrome, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the effect of diltiazem, a calcium channel blocking drug, on the QT interval in patients with Jervell and Lange-Nielsen syndrome. This will be a single IV dose and acute effects (within minutes) will be observed.
Primary Outcome
QT interval (on 12-lead ECG) in ms
Conditions Studied
Interventions
- DRUG diltiazem
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 4 |
What the finished NCT06534671 record still lists
NCT06534671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Jervell and Lange Nielsen Syndrome appearing as the primary indexed condition, and to 1 intervention - of which diltiazem is the first listed.
NCT06534671 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06534671 about?
NCT06534671 is a clinical study titled "Diltiazem in Jervell and Lange-Nielsen Syndrome". This study will test the effect of diltiazem, a calcium channel blocking drug, on the QT interval in patients with Jervell and Lange-Nielsen syndrome. This will be a single IV dose and acute effects (within minutes) will be observed.
What is the current status of trial NCT06534671?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2024-10-16. Estimated completion is 2024-10-23.
What conditions does trial NCT06534671 study?
This clinical trial studies the following conditions: Jervell and Lange Nielsen Syndrome.
What interventions are being tested in trial NCT06534671?
The interventions under investigation include: diltiazem (DRUG).
Who is sponsoring clinical trial NCT06534671?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06534671 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06534671's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI